Combination therapy led to enhanced tumor infiltration of CD8+ T cells, significantly decreased tumor burden and ascites, and the longest survival in treated mice. Synergistic effects observed as STING agonist converted “cold” tumors (low immune activity) into “hot” tumors (high immune cell infiltration), enhancing carboplatin efficacy and immune checkpoint blockade response. The gene discussed is STING1; the disease is neoplasm.